Imatinib Drug Market 2025 | Investment Opportunities, Market Size & Future Opportunities

Market Size and Growth

The Global Imatinib Drug Market is estimated to reach at a Significant CAGR during the forecast period (2024-2031).

Key Development:

✅ In August 2025, a study by Kidoguchi et al. in Internal Medicine reported that although generic imatinib has been available in Japan since 2014 at about 50-55% of the original price, brand-name Gleevec® still held ~72% market share in Fiscal Year 2022. One factor highlighted is Japan's universal health insurance and high-cost reimbursement systems that reduce out-of-pocket costs for patients.

✅ In November 2024, the FDA approved IMKELDI, an oral liquid formulation of imatinib, for treatment of certain forms of leukemia and other cancers. This is the first oral liquid tyrosine kinase inhibitor (TKI) form of imatinib meant to improve dosing accuracy and help patients (including children) who have difficulty swallowing tablets

✅ In October 2024, Japan implemented the Selective Treatment Fee (SENTEI RYOYOHI) rule, which requires patients who choose Gleevec® over its generic counterparts to pay 25% of the cost difference between Gleevec® and the most expensive generic imatinib. This policy aims to curb healthcare costs while preserving choice.

✅ In October 2024, Inhibikase Therapeutics closed financing of up to US$275 million, to advance IkT-001Pro (a prodrug formulation of imatinib) into late-stage clinical trials for pulmonary arterial hypertension (PAH). The aim is to mitigate safety and tolerability issues seen with earlier imatinib formulations.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/imatinib-drug-market?sb

Imatinib is a targeted cancer therapy drug classified as a tyrosine kinase inhibitor, primarily used to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and other cancers. It works by blocking abnormal proteins that promote cancer cell growth, making it a breakthrough in precision oncology.

Key Players:

-> Sun Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy's Laboratories Ltd, Teva Pharmaceutical Industries Ltd., Mylan N.V., Cipla Inc, and Apotex Inc, Sanofi S.A., Actavis Generics, and others.

Growth Forecast Projected:

The Global Imatinib Drug Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Imatinib Drug Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=imatinib-drug-market

Key Segments:

By Application: Chronic Eosinophilic Leukemia, Philadelphia Positive Chronic Myeloid Leukemia, Hyper-Eosinophilic Syndrome (HES), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Gastrointestinal Stromal Tumors (GIST), Others

By Drug Formulation: Capsules, Tablets

By End Use: Hospital Pharmacies, Ambulatory Surgical Centers, Clinics, Others

Regional Analysis for Imatinib Drug Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Imatinib Drug producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Imatinib Drug revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/imatinib-drug-market?sb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.